PL3823623T3 - Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu - Google Patents
Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemuInfo
- Publication number
- PL3823623T3 PL3823623T3 PL19768898.9T PL19768898T PL3823623T3 PL 3823623 T3 PL3823623 T3 PL 3823623T3 PL 19768898 T PL19768898 T PL 19768898T PL 3823623 T3 PL3823623 T3 PL 3823623T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- multiple sclerosis
- preventing multiple
- aminopyrimidine compound
- substituted aminopyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700977P | 2018-07-20 | 2018-07-20 | |
| US201862730184P | 2018-09-12 | 2018-09-12 | |
| US201962839273P | 2019-04-26 | 2019-04-26 | |
| PCT/IB2019/056198 WO2020016850A1 (en) | 2018-07-20 | 2019-07-19 | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3823623T3 true PL3823623T3 (pl) | 2025-03-24 |
Family
ID=67953828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19768898.9T PL3823623T3 (pl) | 2018-07-20 | 2019-07-19 | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12251382B2 (pl) |
| EP (1) | EP3823623B1 (pl) |
| JP (1) | JP7724151B2 (pl) |
| KR (1) | KR102912872B1 (pl) |
| CN (1) | CN112437665A (pl) |
| AU (2) | AU2019306828A1 (pl) |
| BR (1) | BR112021000893A2 (pl) |
| CA (1) | CA3106772A1 (pl) |
| DK (1) | DK3823623T3 (pl) |
| ES (1) | ES3009670T3 (pl) |
| FI (1) | FI3823623T3 (pl) |
| HR (1) | HRP20241737T1 (pl) |
| HU (1) | HUE069840T2 (pl) |
| IL (1) | IL280197B1 (pl) |
| MX (1) | MX2021000094A (pl) |
| PL (1) | PL3823623T3 (pl) |
| PT (1) | PT3823623T (pl) |
| SG (1) | SG11202100518TA (pl) |
| TW (1) | TWI879737B (pl) |
| UA (1) | UA127744C2 (pl) |
| WO (1) | WO2020016850A1 (pl) |
| ZA (1) | ZA202101118B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173740A1 (en) * | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| EP4370513A1 (en) * | 2021-07-15 | 2024-05-22 | Sandoz Ag | Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one |
| CA3260242A1 (en) | 2022-06-24 | 2023-12-28 | Merck Patent Gmbh | TREATMENT REGIMEN FOR AUTOIMMUNE AND INFLAMMATORY DISEASES |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
| WO2011156900A2 (en) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Compounds, compositions and methods for treatment of multiple sclerosis |
| MX354412B (es) * | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| JP6126131B2 (ja) * | 2012-01-10 | 2017-05-10 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| SI3377484T1 (sl) | 2015-11-17 | 2024-02-29 | Merck Patent Gmbh | Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo |
| US10464923B2 (en) * | 2017-02-27 | 2019-11-05 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
-
2019
- 2019-07-19 ES ES19768898T patent/ES3009670T3/es active Active
- 2019-07-19 MX MX2021000094A patent/MX2021000094A/es unknown
- 2019-07-19 BR BR112021000893-4A patent/BR112021000893A2/pt unknown
- 2019-07-19 CN CN201980048404.9A patent/CN112437665A/zh active Pending
- 2019-07-19 KR KR1020217004655A patent/KR102912872B1/ko active Active
- 2019-07-19 DK DK19768898.9T patent/DK3823623T3/da active
- 2019-07-19 FI FIEP19768898.9T patent/FI3823623T3/fi active
- 2019-07-19 SG SG11202100518TA patent/SG11202100518TA/en unknown
- 2019-07-19 EP EP19768898.9A patent/EP3823623B1/en active Active
- 2019-07-19 JP JP2021503059A patent/JP7724151B2/ja active Active
- 2019-07-19 HU HUE19768898A patent/HUE069840T2/hu unknown
- 2019-07-19 TW TW108125526A patent/TWI879737B/zh active
- 2019-07-19 PT PT197688989T patent/PT3823623T/pt unknown
- 2019-07-19 CA CA3106772A patent/CA3106772A1/en active Pending
- 2019-07-19 PL PL19768898.9T patent/PL3823623T3/pl unknown
- 2019-07-19 US US17/261,407 patent/US12251382B2/en active Active
- 2019-07-19 HR HRP20241737TT patent/HRP20241737T1/hr unknown
- 2019-07-19 UA UAA202100604A patent/UA127744C2/uk unknown
- 2019-07-19 AU AU2019306828A patent/AU2019306828A1/en not_active Abandoned
- 2019-07-19 WO PCT/IB2019/056198 patent/WO2020016850A1/en not_active Ceased
-
2021
- 2021-01-14 IL IL280197A patent/IL280197B1/en unknown
- 2021-02-18 ZA ZA2021/01118A patent/ZA202101118B/en unknown
-
2025
- 2025-05-05 AU AU2025203171A patent/AU2025203171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA127744C2 (uk) | 2023-12-20 |
| JP2021532104A (ja) | 2021-11-25 |
| IL280197A (en) | 2021-03-01 |
| PT3823623T (pt) | 2025-01-06 |
| ZA202101118B (en) | 2025-06-25 |
| CA3106772A1 (en) | 2020-01-23 |
| US20210260060A1 (en) | 2021-08-26 |
| DK3823623T3 (da) | 2025-01-02 |
| KR20210034623A (ko) | 2021-03-30 |
| AU2019306828A1 (en) | 2021-03-11 |
| MX2021000094A (es) | 2021-03-25 |
| CN112437665A (zh) | 2021-03-02 |
| JP7724151B2 (ja) | 2025-08-15 |
| EP3823623A1 (en) | 2021-05-26 |
| HUE069840T2 (hu) | 2025-04-28 |
| TW202019425A (zh) | 2020-06-01 |
| TWI879737B (zh) | 2025-04-11 |
| EP3823623B1 (en) | 2024-10-09 |
| SG11202100518TA (en) | 2021-02-25 |
| US12251382B2 (en) | 2025-03-18 |
| AU2025203171A1 (en) | 2025-05-22 |
| ES3009670T3 (en) | 2025-03-31 |
| BR112021000893A2 (pt) | 2021-04-13 |
| KR102912872B1 (ko) | 2026-01-15 |
| HRP20241737T1 (hr) | 2025-02-28 |
| WO2020016850A1 (en) | 2020-01-23 |
| FI3823623T3 (fi) | 2025-01-09 |
| IL280197B1 (en) | 2026-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL287223B1 (en) | kras g12c inhibitors and methods of using them | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| PL3777419T3 (pl) | System i sposób zapewniania alokacji w dziedzinie czasu w systemie komunikacyjnym | |
| IL284799A (en) | Tyk2 inhibitors and uses thereof | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| IL280761A (en) | Devices and systems for body cavities and methods of use | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| PL3464368T3 (pl) | Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka | |
| MX2019006950A (es) | Metodos para tratar la sinaptopatia coclear. | |
| IL290348A (en) | Surface treatment compositions and methods | |
| IL280348A (en) | Surface treatment compositions and methods | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| PL3823623T3 (pl) | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| IL271464A (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| PL3592355T3 (pl) | Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego | |
| EP3468555C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies |